BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 10733487)

  • 1. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas.
    Vergier B; de Muret A; Beylot-Barry M; Vaillant L; Ekouevi D; Chene G; Carlotti A; Franck N; Dechelotte P; Souteyrand P; Courville P; Joly P; Delaunay M; Bagot M; Grange F; Fraitag S; Bosq J; Petrella T; Durlach A; De Mascarel A; Merlio JP; Wechsler J
    Blood; 2000 Apr; 95(7):2212-8. PubMed ID: 10733487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transformed mycosis fungoides: clinicopathological features and outcome.
    Barberio E; Thomas L; Skowron F; Balme B; Dalle S
    Br J Dermatol; 2007 Aug; 157(2):284-9. PubMed ID: 17573879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.
    Scarisbrick JJ; Prince HM; Vermeer MH; Quaglino P; Horwitz S; Porcu P; Stadler R; Wood GS; Beylot-Barry M; Pham-Ledard A; Foss F; Girardi M; Bagot M; Michel L; Battistella M; Guitart J; Kuzel TM; Martinez-Escala ME; Estrach T; Papadavid E; Antoniou C; Rigopoulos D; Nikolaou V; Sugaya M; Miyagaki T; Gniadecki R; Sanches JA; Cury-Martins J; Miyashiro D; Servitje O; Muniesa C; Berti E; Onida F; Corti L; Hodak E; Amitay-Laish I; Ortiz-Romero PL; Rodríguez-Peralto JL; Knobler R; Porkert S; Bauer W; Pimpinelli N; Grandi V; Cowan R; Rook A; Kim E; Pileri A; Patrizi A; Pujol RM; Wong H; Tyler K; Stranzenbach R; Querfeld C; Fava P; Maule M; Willemze R; Evison F; Morris S; Twigger R; Talpur R; Kim J; Ognibene G; Li S; Tavallaee M; Hoppe RT; Duvic M; Whittaker SJ; Kim YH
    J Clin Oncol; 2015 Nov; 33(32):3766-73. PubMed ID: 26438120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis.
    Diamandidou E; Colome-Grimmer M; Fayad L; Duvic M; Kurzrock R
    Blood; 1998 Aug; 92(4):1150-9. PubMed ID: 9694702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
    Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
    Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors.
    Pulitzer M; Myskowski PL; Horwitz SM; Querfeld C; Connolly B; Li J; Murali R
    Pathology; 2014 Dec; 46(7):610-6. PubMed ID: 25393251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases.
    Benner MF; Jansen PM; Vermeer MH; Willemze R
    Blood; 2012 Feb; 119(7):1643-9. PubMed ID: 22160616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.
    Agar NS; Wedgeworth E; Crichton S; Mitchell TJ; Cox M; Ferreira S; Robson A; Calonje E; Stefanato CM; Wain EM; Wilkins B; Fields PA; Dean A; Webb K; Scarisbrick J; Morris S; Whittaker SJ
    J Clin Oncol; 2010 Nov; 28(31):4730-9. PubMed ID: 20855822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of cytotoxic proteins by neoplastic T cells in mycosis fungoides increases with progression from plaque stage to tumor stage disease.
    Vermeer MH; Geelen FA; Kummer JA; Meijer CJ; Willemze R
    Am J Pathol; 1999 Apr; 154(4):1203-10. PubMed ID: 10233858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of the phenotype on mycosis fungoides prognosis, a retrospective cohort study of 160 patients.
    Jaque A; Mereniuk A; Walsh S; Shear NH; Sade S; Zagorski B; Alhusayen R
    Int J Dermatol; 2019 Aug; 58(8):933-939. PubMed ID: 30761533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycosis fungoides in Taiwan shows a relatively high frequency of large cell transformation and CD56 expression.
    Wang RC; Sakata S; Chen BJ; Chang ST; Hsieh PP; Yang CS; Baba S; Takeuchi K; Chuang SS
    Pathology; 2018 Dec; 50(7):718-724. PubMed ID: 30348505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlations between clinical and pathological features in 17 cases of mycosis fungoides before and after transformation.
    Bittencourt AL; Oliveira PD; Carvalho-Andrade A; Araújo I
    Int J Dermatol; 2015 Sep; 54(9):e327-31. PubMed ID: 26147565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: a clinicopathologic and follow-up study of 51 patients.
    van Doorn R; Scheffer E; Willemze R
    Arch Dermatol; 2002 Feb; 138(2):191-8. PubMed ID: 11843638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective Analysis of Prognostic Factors in 187 Cases of Transformed Mycosis Fungoides.
    Talpur R; Sui D; Gangar P; Dabaja BS; Duvic M
    Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):49-56. PubMed ID: 26702474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic and immunologic features associated with transformation of mycosis fungoides to large-cell lymphoma.
    Cerroni L; Rieger E; Hödl S; Kerl H
    Am J Surg Pathol; 1992 Jun; 16(6):543-52. PubMed ID: 1599034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of MCM-3 and MCM-7 in Primary Cutaneous T-cell Lymphomas.
    Jankowska-Konsur A; Kobierzycki C; Reich A; Grzegrzolka J; Maj J; Dziegiel P
    Anticancer Res; 2015 Nov; 35(11):6017-26. PubMed ID: 26504025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas.
    Quaglino P; Pimpinelli N; Berti E; Calzavara-Pinton P; Alfonso Lombardo G; Rupoli S; Alaibac M; Bottoni U; Carbone A; Fava P; Fimiani M; Mamusa AM; Titli S; Zinzani PL; Bernengo MG;
    Cancer; 2012 Dec; 118(23):5830-9. PubMed ID: 22674564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Staging and Prognostic Factors in Folliculotropic Mycosis Fungoides.
    van Santen S; Roach RE; van Doorn R; Horváth B; Bruijn MS; Sanders CJ; de Pooter JC; van Rossum MM; de Haas ER; Veraart JC; Bekkenk MW; Vermeer MH; Willemze R
    JAMA Dermatol; 2016 Sep; 152(9):992-1000. PubMed ID: 27276223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD30 expression and proliferative fraction in nontransformed mycosis fungoides.
    Edinger JT; Clark BZ; Pucevich BE; Geskin LJ; Swerdlow SH
    Am J Surg Pathol; 2009 Dec; 33(12):1860-8. PubMed ID: 19898220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.